Old Web
English
Sign In
Acemap
>
authorDetail
>
Karin Fjordén
Karin Fjordén
Lund University
Medicine
Diffuse large B-cell lymphoma
Lymphoma
Internal medicine
Oncology
6
Papers
21
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial
2021
British Journal of Haematology
Karin Fjordén
Sara Ekberg
Nevzeta Kuric
Karin E. Smedby
Ingemar Lagerlöf
Thomas Stauffer Larsen
Judit Jørgensen
Peter de Nully Brown
Mats Jerkeman
Show All
Source
Cite
Save
Citations (0)
Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial
2020
Blood
Karin Fjordén
Sara Ekberg
Nevzeta Kuric
Karin Ekstroem Smedby
Ingemar Lagerlöf
Thomas Stauffer Larsen
Judit Jørgensen
Peter de Nully Brown
Mats Jerkeman
Show All
Source
Cite
Save
Citations (1)
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma
2014
PLOS ONE
Minna Taskinen
Riku Louhimo
Satu Koivula
Ping Chen
Ville Rantanen
Harald Holte
Jan Delabie
Marja-Liisa Karjalainen-Lindsberg
Magnus Björkholm
Øystein Fluge
Lars Møller Pedersen
Karin Fjordén
Mats Jerkeman
Mikael Eriksson
Sampsa Hautaniemi
Sirpa Leppä
Show All
Source
Cite
Save
Citations (14)
Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study
2014
Blood
Karin Fjordén
Frida Pauly
Sirpa Leppä
Harald Holte
Magnus Björkholm
Øystein Fluge
Lars Møller Pedersen
Mikael Eriksson
Anna Isinger Ekstrand
Carl Borrebaeck
Mats Jerkeman
Christer Wingren
Show All
Source
Cite
Save
Citations (0)
1